Research Trials

If you have any questions or are interested in participating in one of our clinical research studies, please call us at 402.955.2691 or email us at clinicaltrials@nebraskacancer.com.

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • R1979-HM-2293

    A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)

    Cancer Type: Lymphoma

    Lines of Therapy: 1

    Phase: 3

  • GO45434

    Phase II, Open-Label, Multicenter Study To Evaluate The Optimization Of The Cytokine Release Syndrome Profile For Glofitamab In Combination With Gemcitabine Plus Oxaliplatin In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Cancer Type: Lymphoma

    Lines of Therapy: 2

    Phase: 2

    View Details on ClinicalTrials.gov

  • D763TC00001 (tropion Urothelial-04)

  • CORT125134-558

    A Phase 2, Single-Arm Trial of Relacorilant in Combination with Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients with Metastatic Pancreatic Adenocarcinoma

    Cancer Type: Pancreatic

    Lines of Therapy: 1

    Phase: 3

  • GS-US-595-6184 (ASCENT-05)

    A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

    Cancer Type: BREAST

    Lines of Therapy: 1

    Biomarkers: ER-, PR-, HER2-

    Phase: 3

    View Details on ClinicalTrials.gov

  • CRB-701-02

    A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared with Investigator’s Choice of Capecitabine, Cetuximab, or Docetaxel in Participants with Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated with Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

    Cancer Type: HEAD AND NECK

    Lines of Therapy: 2

    Biomarkers: PD-L1

    Phase: 3

  • CAAA817A12201

    ACTion: A phase II/III, open-label, international, multicenter, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMApositive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy

    Cancer Type: PROSTATE

    Biomarkers: PSMA

    Phase: 2, 3

    View Details on ClinicalTrials.gov

  • BGB-43995-302

    An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

    Cancer Type: BREAST

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

  • AMG-757-20240178

    A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

    Cancer Type: SCLC

    Lines of Therapy: 1

    Biomarkers: DLL3

    Phase: 3

    View Details on ClinicalTrials.gov

  • CAAA617A12402

    A Phase 4, post authorization safety study to investigate long term safety of Lutetium vipivotide tetraxetan in adult participants with prostate cancer

    Cancer Type: PROSTATE

    Phase: 4

    View Details on ClinicalTrials.gov

Purpose   •   Innovation   •   Relationship   •   Excellence

#caringforthegoodlife

© 2026 Nebraska Cancer Specialists  •  Privacy Policy  •  design by Chip Thompson

Meet DOT.
Skip to content